Related references
Note: Only part of the references are listed.Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP
Lei Zhao et al.
BLOOD (2013)
Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization
Bohua Li et al.
CANCER RESEARCH (2013)
Antibody Therapeutics in Cancer
Mark X. Sliwkowski et al.
SCIENCE (2013)
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
Anna Emde et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges
Howard M. Stern
SCIENCE TRANSLATIONAL MEDICINE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
Norma O'Donovan et al.
INVESTIGATIONAL NEW DRUGS (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells
Amelia D'Alessio et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
Marcia R. Campbell et al.
CLINICAL CANCER RESEARCH (2010)
The Protein-Protein Interface Evolution Acts in a Similar Way to Antibody Affinity Maturation
Bohua Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
M. D. Green et al.
ANNALS OF ONCOLOGY (2009)
Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma
Bohua Li et al.
BLOOD (2009)
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Maura N. Dickler et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
E. L. Mayer et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
G. Kroemer et al.
CELL DEATH AND DIFFERENTIATION (2009)
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Carlos L. Arteaga et al.
CLINICAL CANCER RESEARCH (2008)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen
Yong Tang et al.
JOURNAL OF IMMUNOLOGY (2007)
Cancer despite immunosurveillance: immunoselection and immunosubversion
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2006)
A better way for a cancer cell to die
RA Lake et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites
Sandra Gemma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
HER2 therapy - Molecular mechanisms of trastuzumab resistance
Rita Nahta et al.
BREAST CANCER RESEARCH (2006)
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy
T Friess et al.
CLINICAL CANCER RESEARCH (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Immunotherapy: Bewitched, bothered, and bewildered no more
RM Steinman et al.
SCIENCE (2004)
Generalized born model with a simple smoothing function
WP Im et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2003)
Rational design and engineering of therapeutic proteins
SA Marshall et al.
DRUG DISCOVERY TODAY (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors
L Savini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models
PA Kollman et al.
ACCOUNTS OF CHEMICAL RESEARCH (2000)
Share Paper
